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Summary Limonene, a monocyclic monoterpene, occurs naturally in orange peel oil. It has been shown to
exhibit both chemopreventive and chemotherapeutic activity without toxicity in rodent models. In this study
we examined the effect of limonene both at maximally optimal and suboptimal doses and in combination with
suboptimal doses of 4-hydroxyandrostrenedione on nitrosmethylurea-induced rat mammary tumours. A 10%
limonene dose mixed in the diet caused tumour regression in all animals. A 5% limonene dose was only able
to cause regression in 50% of the rats (P <0.05). A suboptimal dose of 4-hydroxyandrostrenedione
(12.5mgkg 1) resulted in tumour re ression in 75% of rats. A combination of 5% limonene with 4-
hydroxyandrostrenedione (12.5mgkg- ) resulted in a greater tumour regression (83.3%) than either agent
given individually (P <0.001 and 0.006 for limonene/4-hydroxyandrostrenedione vs limonene alone and
4-hydroxyandrostrenedione alone respectively).
The monocyclic monoterpene limonene is a natural product
constituting up to 95% of orange peel oil and a considerable
proportion of many other essential oils. Limonene has
significant chemopreventive and chemotherapeutic activity
without toxicity in rodents (Elegbede et al., 1984, 1986; Elson
et al., 1988; Maltzman et al., 1989; Wattenberg et al., 1989,
1991). Most studies have been directed at the use of limonene
in the prevention of carcinogen-induced cancer (Wattenberg
et al., 1983; Elegbede et al., 1984). It has been shown that
limonene inhibits rat mammary carcinomas induced by both
the indirectly acting carcinogen DMBA (Elegbede et al.,
1984) and the directly acting carcinogen NMU (Maltzman et
al., 1989). The inhibitory effect of limonene was observed at
both the initiation and promotion/progression stages for
DMBA-induced cancers (Elson et al., 1988), but only at the
promotion/progression stage for NMU-induced mammary
cancer (Maltzman et al., 1989).
The suppressive activity of limonene during the promotion
phase of rat mammary carcinogenesis has been demonstrated
in both chemical carcinogen (Maltzman et al., 1989) and
ras-induced (Moore et al., 1991) model systems. Rats fed a
diet containing 5% limonene during the promotion phase
only of the NMU model exhibited longer latency and ap-
proximately 5-fold fewer tumours than controls (Maltzman et
al., 1989).
It has been shown that limonene can selectively inhibit
protein isoprenylation (Crowell et al., 1991), a post-
translational modification in which an isoprene group is
covalently attached to the carboxy terminus. Most of the
isoprenylated proteins affected by limonene have a molecular
weight of 20,000-26,000 (Crowell et al., 1991) and are small
G-proteins such as the members of the p21-ras family
(Maltese et al., 1990).
The effectiveness of limonene alone on NMU-induced rats
has already been shown by previous workers (Haag et al.,
1992). In this study the possibility of using limonene in
combination with 4-hydroxyandrostenedione (4-HAD), a
potent aromatase inhibitor, was investigated to explore
whether the inhibitory activity of suboptimal doses of 4-
HAD and limonene when given together could result in
greater inhibition of NMU-induced tumour growth than
either of these agents alone. Such an approach could open
new avenues for using limonene in combination therapy.
Materials and methods
In vivo studies
Inbred virgin female (Ludwig/Wistar/Olac) rats bearing
tumours induced with NMU were supplied by Olac (Oxon,
UK). These were used in the manner described previously
(Wilkinson et al., 1986). In all studies, adult rats bearing
tumours between 10 and 20 mm in diameter were random-
ised. All rats were treated daily with appropriate drug for 4
weeks. Tumour measurements were made weekly for 4 weeks
by measuring two diameters at right angles with vernier
callipers. Tumour volume was estimated using the following
formula:
Jt/6 [(d1 x d2)12]
where d, and d2 are the two diameters at right angles to each
other.
At the end of the 4-week period, all palpable lesions were
removed from the mammary area and stored in liquid nit-
rogen and subsequently used for histological examination.
Drug schedules
Limonene alone Rat high-fat diet (SDS, UK) was powdered
using a food processor and then the required amount of
limonene (w/v), supplied by Aldridge (USA), was added to
the powdered diet to give a final 10% limonene in the diet.
The diet (prepared weekly) was placed in plastic bags and
kept at
- 20°C until required. Rats were fed fresh diet
daily (for 4 weeks) by placing in glass jars in the cages.
4-Hydroxyandrostrendione alone A suboptimal dose of
12.5 mg kg-' 4-HAD (Ciba Geigy) was resuspended in saline
and formed a white suspension, which was administered daily
at a dose of 12.5 mg kg-' (2.5 mg 0.1 ml-' per rat) sub-
cutaneously for 4 weeks. A dose of 50 mg kg-' 4-HAD has
previously been shown to be maximally effective (Wilkinson
et al., 1986).
Combination therapy Rats were given a 5% (suboptimal)
dose of limonene in the diet as detailed above. 4-Hydroxy-
androstrenedione in combination was given subcutaneously
at a suboptimal dose of 12.5 mg kg-', daily for 4 weeks.
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Histological studies
At the end of the 4 week period of drug treatment animals
were sacrificed and tumours were resected and immediately
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frozen in liquid nitrogen. Frozen sections (8ftm) were stained
using standard haematoxylin and eosin, and examined for
morphological changes.
Results
Limonene treatment
The effect of 10% limonene in the diet on the growth of
NMU-induced tumours is shown in Figure 1. After 4 weeks'
treatment, limonene produced tumour regression in all rats.
Eighty-six per cent of the animals (13/15) exhibited greater
than 50% tumour regression (Table I). Any new tumours
that occurred after commencement of treatment also subse-
quently regressed in the limonene group. In the control group
two (13.3%) rats showed tumour regression. Thus, limonene
treatment produced a significantly beneficial response com-
pared with control (Mann-Whitney U = 1, P <0.05). We
observed no weight loss at this dose of limonene.
Limonene in combination with 4-hydroxyandrostenedione
The combination of suboptimal doses of 4-HAD with a
suboptimal dose of limonene (5%) was compared and the
results are shown in Figure 2. A 5% limonene dose only
produced overall tumour regression of 50% (6/12) of rats,
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Figure 1 The effect of limonene on the growth of NMU-induced
rat mammary tumours. Limonene was mixed into powdered diet
to give a final 10% in diet and rats were fed, with daily changes,
for 4 weeks. Tumour measurements were made weekly and the
tumour volume calculated as described in Materials and methods.
Results are expressed as the percentage change from the starting
tumour volume. Error bars represent s.e.m.
Table I Effect of 10% limonene on the growth of NMU-induced
rat mammary tumours
Groups
Limonene
(10% diet) Control
No. of rats 15 15
No. of new tumours 1 0
No. of rats showing <50% regression 2 2
No. of rats showing >50% regression 13 0
No. of rats showing progression 0 13
Percentage of rats showing >50% 86.6 0
regression
Percentage of rats showing any regression 100 13.3a
Rats were given limonene or vehicle daily for 4 weeks. Tumour
growth was recorded every week for the 4-week period, by measuring
two diameters at right angles with vernier callipers and tumour
volume was estimated as described in Materials and methods. Each
of the animals was categorised into one of three groups: (a) 50% or
greater tumour regression; (b) 0-50% tumour regression; (c) tumour
progression. aMann-Whitney U = 1, P <0.05.
but only 25% of animals showed > 50% tumour regression.
4-HAD administered alone caused regression in 75% (9/12)
of rats. Moreover, 58% (7/12) of rats showed > 50% tumour
regression. However, in combination, limonene plus 4-HAD
caused regression in 83.3% (10/12) of rats, and this level of
response was significantly greater than that achieved with the
individual agents alone (P-values as given in Table II). The
weights of rats were also recorded throughout the experiment
and there was no significant loss compared with controls
[mean weights in g (± s.d.) after 4 weeks: control = 198 + 18,
limonene alone = 194 ± 19; 4-HAD alone = 207 ± 12;
limonene + 4-HAD = 206 ± 9].
Histological studies
Control group Eight representative excised mammary
tumours were examined. One consisted of loosely packed
adenoid tissue with fibrous tissue separating acinar tissue.
Mitoses were not seen frequently and cellular characteristics
showed this tumour to be a benign fibroadenoma. The other
seven tumours were classified as adenocarcinoma. They
exhibited characteristic cellular pleomorphism, abundant
mitoses and prominent papillary growth (Figure 3). Epithelia
were commonly multilaminate. In some tumours, large acinar
cavities or cysts were present and containing variable
amounts of cell debris. Four of the tumours were well-
differentiated carcinomas; their cellularity was more intense
and papillary tufts prominent.
Limonene-treated group Two tumours out of 15 examined
were quite benign. They contained some large debris-filled
cavities, showed no evidence of proliferative activity and
consisted of acinar tissue interspersed with connective tissue
characteristic of adenocarcinoma, but for the most part the
tissue was hypocellular, fragmentary and regressive (Figure
4). Some residual evidence of malignancy in the form of
papillary tufts with pleomorphic cells and hypocellularity was
seen, but mitotic activity was very low. These tumours
exhibited fragmentary epithelia and were generally regressive.
Those rats treated with the combination of limonene and
4-HAD also showed similar characteristics to the limonene-
treated groups.
Discussion
Data presented in this study support previous findings that a
10% limonene dose in the diet is sufficient to cause tumour
regression (Haag et al., 1992); limonene showed regression in
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Figure 2 The effect of (suboptimal dose) 5% limonene and
12.5 mg kg-' 4-HAD administered separately and in combination
on the growth of NMU-induced rat mammary tumours. Rats
were treated daily for 4 weeks and tumour measurements made
weekly. (0) control, (0) 5% limonene alone in diet, (0); 4-
HAD alone given s.c., (-) 5% limonene (in diet) plus 4-HAD
given s.c. Error bars represent s.e.m.EFFECT OF LIMONENE AND 4-HAD ON NMU-INDUCED RAT MAMMARY TUMOURS 881
Table II Effect of 5% limonene/4-HAD on NMU-induced rat mammary tumours
Treatment groups
4-HAD 5% limonene
Control 5% limonene (12.5 mgkg-') + 4-HAD
No. ofrats 12 12 12 12
No. ofinitial tumour 20 19 14 16
(.>10 mm)
No. ofnew tumours 2 0 1 0
No. ofrats showing 1 2 2 0
<50% regression
No. ofratsshowing 0 4 7 10
>50% regression
No. ofrats showing 11 6 3 2
progression
Percentage ofrats 0.0 33.3 58.3 83.3
showing > 50%
regression
Percentageofrats 8.3 50.0 75 83.3a
showing any
regression
Rats were given either drug or vehicle (as described in Materials and methods) daily for
4 weeks. Tumour growth was recorded every week over the 4 week period, by measuring
two diameters at right angles with vernier callipers, and tumour volume was estimated
using the formula given in Materials and methods. Animals were categorised into three
groups: (a) 50% or greater tumour regression; (b) 0-50% tumour regression; (c) tumour
progression. aMann-Whitney U-test: limonene + 4-HAD vs control, P <0.001;
limonene + 4-HAD vs limonene, P <0.001; limonene + 4-HAD vs 4-HAD, P = 0.006.
Figure 3 Frozen section (stained with haematoxylin and eosin)
of an NMU-induced rat mammary adenocarcinoma. Note dense
cellular mass, papilliform growths and multilaminate epithelia.
Magnification x 65.
100% of rats, and 86.6% of rats showed >50% regression
from the initial tumour volume. The histological studies
showed that treatment with limonene caused regression of
tumour mass, as most of the tissue showed regressive
fragmentary epithelia.
The most significant finding was that suboptimal doses of
an aromatase inhibitor, 4-HAD, could be used in combina-
tion with a suboptimal dose of limonene to produce regres-
sion in rats similar to that obtained with maximally effective
doses of either limonene or 4-HAD separately. This suggests
that the full potential of limonene in the treatment of breast
cancer can be realised in a combination therapy minimising
risk of toxicity, which might occur if higher doses were used
in chronic treatment.
The mode of action of 4-HAD has been well studied
(Coombes et al., 1984) but the precise mechanism of action
of limonene still remains to be elucidated. Crowell et al.
(1991) recently reported that, in cultured fibroblasts and
mammary epithelia, limonene and its major circulating meta-
bolites selectively inhibited the isoprenylation of cellular pro-
teins, in particular those in the molecular weight range of
20,000-26,000. Most of these are small G-proteins that are
likely to be involved in signal transduction (Maltese et al.,
Figure 4 Haematoxylin and eosin-stained frozen section of
NMU-induced rat mammary tumour illustrating fragmentary
epithelia in a mammary tumour mass after treatment with
limonene. Magnification x 130.
1990). Isoprenylation of these proteins involves the covalent
addition of either farnesyl or geranyl-geranyl moieties to the
carboxyl end of the protein. Inhibition of this hydrophobic
post-translational modification prevents the protein from
assuming its correct subcellular location, thus interfering with
its function. Haag et al. (1992) speculated that this very
selective but partial inhibition of this isoprenylation of small
G-proteins may be involved with the regression of certain
tumours, and therefore this process could be a potentially
useful target for cancer therapeutic strategies.
Crowell et al. (1991) have recently shown that there are
more potent monoterpene inhibitors ofprotein isoprenylation
than limonene, such as perillic and dihydroperillic acid,
which are found as active metabolites in rats (Crowell et al.,
1991). These could potentially be used in smaller doses than
limonene. It will also be useful to extend this in vivo evalua-
tion of limonene and similarly active agents to other tumour
types in addition to mammary carcinomas.
Abbreviations: 4-HAD, 4-hydroxyandrostenedione; NMU, nitros-
methylurea; DMBA, dimethylbenz[a]anthracene.882 S.K. CHANDER et al.
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